October 2, 2007 - TherOx Inc., a privately held medical device company, will announce at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington D.C. on October 23, the results from its pivotal trial, AMIHOT II (Acute Myocardial Infarction with Hyperoxemic Oxygen Therapy), designed to introduce a new therapy developed by THEROX called SuperOxygenation Therapy.
The multi-center, randomized trial included more than 300 STEMI (ST-segment Elevation Myocardial Infarction) patients and introduced a new treatment category called Myocardial Salvage Intervention (MSI). SuperOxygenation Therapy is an adjunctive therapy performed immediately after Percutaneous Coronary Intervention (PCI) in Acute Myocardial Infarction (AMI) patients. Myocardial Salvage Intervention is a new treatment category for AMI patients designed to salvage the jeopardized myocardium and reduces infarct size.
AMIHOT II was derived from a subset of the original AMIHOT study population consisting of anterior AMI patients treated within 6 hours from symptom onset. Effectiveness was assessed by infarct size reduction measured by SPECT at 14 days post event, and safety was determined by the 30-day MACE (Major Adverse Cardiac Events) rate. MACE comprised combined incidence of death, reinfarction, target vessel revascularization and stroke.
For more information: www.therox.com
November 18, 2024 
